Dana-Farber Cancer Institute
Open enrollment with an early-phase pipeline tilt
According to ClinicalTrials.gov-derived indexes, Dana-Farber Cancer Institute sits in the top decile of US sponsors by registered trial count (#42 of 15,742 sponsors by registered trial count).
Dana-Farber Cancer Institute: 781 sponsored US clinical trials, 112 recruiting.
Dana-Farber Cancer Institute sponsors 781 registered US clinical trials on ClinicalTrials.gov, 112 of them currently recruiting, and 449 completed. 15 of these trials are in Phase 3-4 (later-stage) and 492 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Breast Cancer, with 53 trials.
Top-decile sponsor footprint
Dana-Farber Cancer Institute ranks in the top decile of sponsors by registered trial count (#42 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.
Trial completion reliability score
449 of 537 decided trials (Completed vs. Terminated on ClinicalTrials.gov) reached their planned completion (83.6%), vs. national p10 68.4% / p90 100% among 1,234 sponsors with at least 10 decided trials. Still-open trials (Recruiting, Active-not-recruiting, Not-yet-recruiting) are excluded since they have not reached an outcome yet.
Open and recent trials
781 total, page 7 of 16
Pilot Feasibility of the Pediatric Cancer Resource Equity (PediCARE) Intervention
NCT03638453
Young, Empowered & Strong (YES): The Young Women's Breast Cancer Study 2- Focus on Intervention Pilot
NCT03913936
Individualizing Surveillance Mammography for Older Breast Cancer Survivors
NCT03865654
The PRISM Intervention: a Multi-site Randomized Controlled Trial for Adolescents and Young Adults With Advanced Cancer
NCT03668223
Improving Quality of Life of Prostate Cancer Survivors With Androgen Deficiency
NCT03716739
EHR-embedded OCDT in Breast or GI Cancer
NCT03858712
GDC-0084 in Combination With Trastuzumab for Patients With HER2-Positive Breast Cancer Brain Metastases
NCT03765983
A Feasibility Study of Durvalumab +/- Oleclumab as Neoadjuvant Therapy for Muscle-invasive Bladder Cancer (BLASST-2)
NCT03773666
Acceptance and Commitment Therapy (ACT) - Based Treatment Development for Cancer Patients Treated for Pain
NCT03910296
Mindfulness-Music Intervention for Adolescents and Young Adults With Cancer
NCT03709225
Prexasertib in Combination With MEC in Relapsed/Refractory AML and High Risk MDS - a Phase I Trial
NCT03735446
Acupuncture for Hot Flashes in Hormone Receptor-Positive Breast Cancer, a Randomized Controlled Trial
NCT03783546
Avelumab and Radiation in Muscle-Invasive Bladder Cancer
NCT03747419
Safety and Efficacy of Nivolumab in Treating Oral Proliferative Verrucous Leukoplakia
NCT03692325
Paricalcitol Plus Gemcitabine and Nab-paclitaxel in Metastatic Pancreatic Cancer
NCT03520790
Sexual Health and Rehabilitation After Ovarian Suppression Treatment
NCT03571841
Testing Feasibility of Motivational Interviewing for Patient-Reported Cancer Pain Goals
NCT03736746
Mathematical Model-Adapted Radiation In Glioblastoma
NCT03557372
Smartphone Technology to Alleviate Malignant Pain (STAMP)
NCT03717402
Phase 1 Study of the Dual MDM2/MDMX Inhibitor ALRN-6924 in Pediatric Cancer
NCT03654716
Rituximab + Immunotherapy in Follicular Lymphoma
NCT03636503
Peri-Transfusion QOL Assessments (PTQA): A New Paradigm of Transfusion Decision Support for Patients With MDS
NCT03660228
Pembrolizumab and Reirradiation in Bevacizumab Naïve and Bevacizumab Resistant Recurrent Glioblastoma
NCT03661723
MCS110 With BRAF/MEK Inhibition in Patients With Melanoma
NCT03455764
EL CENTRO: Engaging Latinos in the Center of Cancer Treatment Options
NCT03602885
Study of Venetoclax, a BCL2 Antagonist, for Patients With Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN)
NCT03485547
Web-based Insomnia Treatment for Adolescent and Young Adult Cancer Survivors
NCT03279055
Prospective Study of BK Virus Disease After Allogeneic Hematopoietic-cell Transplantation: Defining BK Disease's Natural History, Clinical Spectrum, Immunology, and Outcomes
NCT03532971
SHARE (Sharing Goals and Preferences) Study
NCT03392090
Stepping Into Survivorship: Harnessing Behavioral Economics to Improve Quality of Life in Ovarian Cancer
NCT03364673
The GI Binder: A Psychoeducational Intervention for Gastrointestinal Cancer Patients
NCT03576872
Clinician Decision Support Algorithm for Chemotherapy-Induced Peripheral Neuropathy
NCT03514680
Durvalumab, Tremelimumab + Radiotherapy in Gynecologic Cancer
NCT03277482
A Study of Prexasertib (LY2606368), CHK1 Inhibitor, and LY3300054, PD-L1 Inhibitor, in Patients With Advanced Solid Tumors
NCT03495323
Role of Contrast Enhanced Spectral Mammography to Predict Upgrade Rates of Biopsy Proven Atypical Ductal Hyperplasia
NCT03505372
Pembrolizumab (Anti-PD-1) and AMG386 (Angiopoietin-2 (Ang-2) in Patients With Advanced Solid Tumor
NCT03239145
BOLSTER: Building Out Lifelines for Safety, Trust, Empowerment and Renewal
NCT03367247
Study of Pancreatic Enzyme Replacement on Completion of Adjuvant Chemotherapy for Resected Pancreatic Adenocarcinoma
NCT03469258
Biomarkers of Response to Ipilimumab and Nivolumab in First-line NSCLC
NCT03425331
A Phase II Study of BVD-523 in Metastatic Uveal Melanoma
NCT03417739
Understanding Barriers to Initiation and Adherence to Endocrine Therapy in Young Breast Cancer Survivors of Diverse Backgrounds
NCT03447886
Ivabradine in the Management of Cardiac Autonomic Dysfunction Associated With Thoracic Radiation Therapy.
NCT03137537
HealthSmart: Promoting Healthy Lifestyles for Young Adult Cancer Survivors Using Educational Videos
NCT03340532
Study of Gemcitabine, Nab-paclitaxel, and Ficlatuzumab (AV-299) in Patients With Advanced Pancreatic Cancer
NCT03316599
A Nurse Led Project to Introduce Hand Lettering as a Form of Creative Art Expression to Patients in an Ambulatory Oncology Setting
NCT03291730
Shared Care: Patient-Centered Management After Hematopoietic Cell Transplantation
NCT03244826
Exercise Intervention Among Men With Prostate Cancer Initiating Androgen Deprivation Therapy
NCT03070145
Physical Activity In Gastrointestinal Cancer
NCT03331406
A Phase II Study of Nivolumab in Combination With Cabozantinib for Metastatic Triple-negative Breast Cancer
NCT03316586
A Study of Daratumumab in Patients With Relapsed or Refractory Waldenström Macroglobulinemia
NCT03187262
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 181 |
| Phase 2 | 311 |
| Phase 3 | 14 |
| Phase 4 | 1 |
Therapeutic Areas
What is open in the Dana-Farber Cancer Institute pipeline
112 recruiting of 781 indexed (14% open); 449 completed (57%).
Phase mix: 15 late (III/IV) vs 492 early (I/II) (early-phase heavy).
Top condition: Breast Cancer (53 trials), 9 others listed.
How open-pipeline share is computed
Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.
Dana-Farber Cancer Institute: open-pipeline peers nationwide
Peers matched on 781 registered trials and 14% open enrollment, not the therapeutic-area sidebar.
Dana-Farber Cancer Institute sits at or above the median trial volume and below the median recruiting share among these 9 nationwide peers -- the two do not always move together.
Sponsors near 781 trials (± recruiting share)
- University of California, San Diego · 775 trials · 18% recruiting
- University of Chicago · 796 trials · 20% recruiting
- Medical University of South Carolina · 755 trials · 19% recruiting
- University of Utah · 818 trials · 17% recruiting
Sponsors near 14% open enrollment (± trial volume)
- The Cleveland Clinic · 14% recruiting · 688 trials
- Academic and Community Cancer Research United · 14% recruiting · 42 trials
- Adaptive Biotechnologies · 14% recruiting · 7 trials
- AgelessRx · 14% recruiting · 7 trials
Related
What to do with this Dana-Farber Cancer Institute page
781 registered trials is a research-attention snapshot, not an endorsement of Dana-Farber Cancer Institute or any single study.
- 112 of Dana-Farber Cancer Institute's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
- Breast Cancer is the condition Dana-Farber Cancer Institute studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Breast Cancer trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. Dana-Farber Cancer Institute pipeline card: 781 registered trials from official public datasets. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.